Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
ASC or Extreme Reach?
-
A few of our clients on the consumer side (DTC, OTC) have been asking us about an Extreme Reach pre-clearance review instead of ASC. Can you confirm if they are in fact interchangable? Wanted to make sure that PAAB would recognise both.
-
Please note that this is not a PAAB Code issue per se. Extreme Reach is MIJO in the following Health Canada policy document:
Health Canada provides a list of preclearance agencies on their site:
-
@jennifer-carroll Thanks for the clarification Jen. Just to confirm, given that they are both recognised by Health Canada on their list of preclearence Agencies we can use either body. Have a great weekend.
-
DTC for OTCs is out of the PAAB Code’s scope. We do not comment on, or endorse, any particular agency in the DTC space for OTCs. The PAAB encourages preclearance of DTC/OTC materials by a Health Canada recognized agency.
